Abbott Laboratories (ABT) Institutional Ownership & Insider Trading

2,959 institutions reported holding Abbott Laboratories shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 17 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ABTAbbott LaboratoriesFollow ABT — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 179.4B
P/E TTM: 33.5
Dividend yield: 2.4%
52-week: —
Next earnings: 20 Jan, in 88 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

2,959 institutions held 79.8% of the shares. Across filers that reported both quarters, shares held changed -1.6%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	2,959	1381	-1.6%	899	126	1195	236
Mar 26	3,055	1374	-0.9%	863	103	1172	257
Dec 25	3,187	1395	-0.5%	812	97	1029	137
Sep 25	3,102	1380	+1.9%	840	103	960	85
Jun 25	3,111	1371	+0.4%	972	109	894	92
Mar 25	3,081	1343	+1.2%	828	199	1006	79
Dec 24	2,945	1345	+0.8%	817	74	838	78
Sep 24	2,816	1284	-4.2%	779	115	897	89

Abbott Laboratories — questions

Who owns Abbott Laboratories stock?: 2,959 institutions reported Abbott Laboratories shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (8.8%), VANGUARD CAPITAL MANAGEMENT LLC (6.6%), STATE STREET CORP (4.7%).
Are Abbott Laboratories insiders buying or selling?: 17 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Abbott Laboratories's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.